文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

患者与诊所工作人员对在城市安全网卫生系统中实施长效注射抗逆转录病毒治疗项目的看法。

Patient and clinic staff perspectives on the implementation of a long-acting injectable antiretroviral therapy program in an urban safety-net health system.

作者信息

Agovi Afiba Manza-A, Thompson Caitlin T, Craten Kevin J, Fasanmi Esther, Pan Meng, Ojha Rohit P, Thompson Erika L

机构信息

Center for Epidemiology & Healthcare Delivery Research, JPS Health Network, 1500 South Main Street, Fort Worth, TX, 76104, USA.

Pharmacy Clinical Services Outpatient, JPS Health Network, Fort Worth, TX, USA.

出版信息

Implement Sci Commun. 2024 Aug 29;5(1):93. doi: 10.1186/s43058-024-00631-7.

DOI:10.1186/s43058-024-00631-7
PMID:39210473
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11363636/
Abstract

BACKGROUND: Long-acting injectable cabotegravir plus rilpivirine (LAI CAB/RPV) has several potential benefits over daily oral formulations for HIV treatment, including the potential to facilitate long-term adherence and reduce pill fatigue. We aimed to assess facilitators of and barriers to LAI CAB/RPV implementation and delivery through the perspectives of physicians and clinical staff, and the experiences of LAI CAB/RPV use among people living with HIV (PLWH) at a Ryan-White supported safety-net clinic in North Texas. METHODS: We conducted semi-structured interviews with recruited clinic staff (physicians, nurses, and support staff) involved with LAI CAB/RPV implementation and PLWH who switched to LAI CAB/RPV and consented to participate in individual interviews. Data were collected from July to October 2023. Our interview guide was informed by the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM), and Proctor Implementation Outcomes frameworks. Qualitative data were analyzed using a rapid qualitative analysis approach to summarize key themes. RESULTS: We recruited and interviewed 15 PLWH who transitioned to LAI CAB/RPV and 11 clinic staff serving these patients. PLWH conveyed that emotional and informational support from family or a trusted clinician influenced their decision to switch to LAI CAB/RPV. PLWH also reported that injectable treatment was more effective, convenient, and acceptable than oral antiretroviral therapy. Clinic staff and physicians reported that staff training, pharmacist-led medication switches, flexible appointments, refrigeration space and designated room for injection delivery facilitated implementation. Clinic staff cited medication costs, understaffing, insurance prior authorization requirements, and lack of medication access through state drug assistance programs as critical barriers. CONCLUSIONS: Our study offers insights into real-world experiences with LAI usage from the patient perspective and identifies potential strategies to promote LAI CAB/RPV uptake. The barriers to and facilitators of LAI CAB/RPV program implementation reported by clinic staff in our study may be useful for informing strategies to optimize LAI CAB/RPV programs.

摘要

背景：长效注射用卡博特韦加rilpivirine（LAI CAB/RPV）在HIV治疗方面相对于每日口服制剂具有若干潜在优势，包括有助于长期坚持治疗并减轻服药负担。我们旨在从医生和临床工作人员的角度评估LAI CAB/RPV实施和给药的促进因素及障碍，以及在北德克萨斯州一家由瑞安·怀特基金支持的安全网诊所中HIV感染者（PLWH）使用LAI CAB/RPV的体验。 方法：我们对参与LAI CAB/RPV实施的招募诊所工作人员（医生、护士和支持人员）以及转而使用LAI CAB/RPV并同意参加个人访谈的PLWH进行了半结构化访谈。数据收集于2023年7月至10月。我们的访谈指南参考了可及性、有效性、采用、实施、维持（RE-AIM）和普罗克特实施结果框架。使用快速定性分析方法对定性数据进行分析以总结关键主题。 结果：我们招募并访谈了15名转而使用LAI CAB/RPV的PLWH以及为这些患者服务的11名诊所工作人员。PLWH表示，来自家人或值得信赖的临床医生的情感和信息支持影响了他们转而使用LAI CAB/RPV的决定。PLWH还报告称，注射治疗比口服抗逆转录病毒疗法更有效、更方便且更易接受。诊所工作人员和医生报告称，工作人员培训、药剂师主导的药物转换、灵活的预约安排、冷藏空间和指定的注射给药室促进了实施。诊所工作人员指出，药物成本、人员配备不足、保险预先授权要求以及通过州药物援助计划无法获得药物是关键障碍。 结论：我们的研究从患者角度提供了关于LAI使用的真实世界体验的见解，并确定了促进LAI CAB/RPV采用的潜在策略。我们研究中诊所工作人员报告的LAI CAB/RPV项目实施的障碍和促进因素可能有助于为优化LAI CAB/RPV项目的策略提供信息。

相似文献

[1]
Patient and clinic staff perspectives on the implementation of a long-acting injectable antiretroviral therapy program in an urban safety-net health system.

Implement Sci Commun. 2024-8-29

[2]
Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida.

AIDS Patient Care STDS. 2024-6

[3]
Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South.

Open Forum Infect Dis. 2022-9-2

[4]
Long-Acting Injectable ART in Practice: A Mixed Methods Implementation Study Assessing the Feasibility of Using LAI ART in High Risk Populations and At Alternative Low Barrier Care Sites.

AIDS Patient Care STDS. 2024-5

[5]
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.

Ther Adv Infect Dis. 2023-12-13

[6]
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).

Patient. 2021-11

[7]
Early Implementation and Outcomes Among People with HIV Who Accessed Long-Acting Injectable Cabotegravir/Rilpivirine at Two Ryan White Clinics in the U.S. South.

AIDS Res Hum Retroviruses. 2024-12

[8]
Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS™ App and Web Portal: A Cluster Randomized Trial.

J Int Assoc Provid AIDS Care. 2024

[9]
Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations.

J Int AIDS Soc. 2024-7

[10]
Implementation of a Pharmacist-Led, Long-Acting, Injectable Cabotegravir/Rilpivirine Program for HIV-1 at Health System-Based Clinics in the New York Metropolitan Area.

AIDS Patient Care STDS. 2024-3

引用本文的文献

[1]
Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study.

Viruses. 2025-7-16

[2]
Early Implementation of Long-Acting Injectable Cabotegravir for HIV Prevention in a Safety Net Hospital-based Primary Care Center in U.S. South.

J Gen Intern Med. 2025-2-11

[3]
Receipt of long-acting injectable antiretroviral therapy among people with HIV in Southern US states: an assessment using electronic health records and claims data.

AIDS Res Ther. 2025-2-1

本文引用的文献

[1]
Long-acting injectable ART to advance health equity: a descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for implementation from applications to the ALAI UP Project.

J Int AIDS Soc. 2024-7

[2]
Early Implementation and Outcomes Among People with HIV Who Accessed Long-Acting Injectable Cabotegravir/Rilpivirine at Two Ryan White Clinics in the U.S. South.

AIDS Res Hum Retroviruses. 2024-12

[3]
Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida.

AIDS Patient Care STDS. 2024-6

[4]
Long-Acting Injectable ART in Practice: A Mixed Methods Implementation Study Assessing the Feasibility of Using LAI ART in High Risk Populations and At Alternative Low Barrier Care Sites.

AIDS Patient Care STDS. 2024-5

[5]
Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States.

AIDS Behav. 2024-7

[6]
Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir-Rilpivirine in People With HIV Who Are Virally Unsuppressed.

J Acquir Immune Defic Syndr. 2024-7-1

[7]
Implementation of a Pharmacist-Led, Long-Acting, Injectable Cabotegravir/Rilpivirine Program for HIV-1 at Health System-Based Clinics in the New York Metropolitan Area.

AIDS Patient Care STDS. 2024-3

[8]
Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel.

JAMA. 2024-3-26

[9]
Long-Acting Injectable Antiretrovirals for HIV Treatment: A Multi-Site Qualitative Study of Clinic-Level Barriers to Implementation in the United States.

AIDS Patient Care STDS. 2024-2

[10]
Assessing readiness to implement long-acting injectable HIV antiretroviral therapy: provider and staff perspectives.

Implement Sci Commun. 2023-10-19

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索